Analysts expect Replimune Group Inc (NASDAQ:REPL) to post earnings per share of ($0.39) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Replimune Group’s earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.44). Replimune Group reported earnings per share of ($0.24) during the same quarter last year, which would indicate a negative year over year growth rate of 62.5%. The company is expected to announce its next earnings report on Thursday, February 13th.
According to Zacks, analysts expect that Replimune Group will report full-year earnings of ($1.41) per share for the current financial year, with EPS estimates ranging from ($1.52) to ($1.26). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.89) to ($1.46). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Replimune Group.
Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01).
In other Replimune Group news, Chairman Philip Astley-Sparke sold 14,500 shares of Replimune Group stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $247,225.00. Also, COO Colin Love sold 11,250 shares of Replimune Group stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $191,812.50. Insiders have sold a total of 200,000 shares of company stock valued at $3,395,500 in the last ninety days. Insiders own 63.18% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley grew its holdings in shares of Replimune Group by 793.0% during the second quarter. Morgan Stanley now owns 20,709 shares of the company’s stock worth $304,000 after purchasing an additional 18,390 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Replimune Group by 211.3% during the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after purchasing an additional 15,672 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Replimune Group by 1.2% during the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock worth $1,817,000 after purchasing an additional 1,437 shares in the last quarter. Citadel Advisors LLC grew its holdings in shares of Replimune Group by 5.7% during the second quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock worth $2,731,000 after purchasing an additional 10,009 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Replimune Group by 7.3% during the second quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock worth $7,866,000 after purchasing an additional 36,547 shares in the last quarter. 60.92% of the stock is owned by institutional investors.
NASDAQ:REPL traded down $1.44 during trading hours on Tuesday, hitting $12.20. 819,800 shares of the company traded hands, compared to its average volume of 194,376. Replimune Group has a one year low of $8.88 and a one year high of $18.25. The firm’s 50-day simple moving average is $14.49 and its 200-day simple moving average is $13.44. The company has a market cap of $436.60 million, a PE ratio of -9.17 and a beta of 3.30. The company has a quick ratio of 9.79, a current ratio of 9.85 and a debt-to-equity ratio of 0.16.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Article: Why do companies issue monthly dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.